Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[leifsmith]

Right. This is no ordinary phase 1 trial. It goes far beyond and will produce the kind of results expected from a phase 3 because it measures a therapeutic effect, one known to be beneficial in many disease states.

However, since the therapeutic effect to be measured is reduction of inflammation, and not the consequence of inflammation in any specific disease, it seems that more trials, targeting specific diseases, will be required before a product can be marketed.

The length of such trials, in many cases, might be short.

Do you agree with this?